Mangoceuticals (MGRX) Net Income towards Common Stockholders (2023 - 2026)

Mangoceuticals has disclosed Net Income towards Common Stockholders across 4 years of filings, most recently posting -$1.6 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders rose 71.86% year-over-year to -$1.6 million; the TTM figure through Jun 2026 stood at -$16.3 million (down 7.92% YoY), while the FY2025 annual figure was -$21.8 million, down 129.47% from the prior year.
• Net Income towards Common Stockholders came in at -$1.6 million for Q2 2026 at Mangoceuticals, up from -$3.7 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.6 million in Q2 2026 to a low of -$7.9 million in Q3 2025.
• Average Net Income towards Common Stockholders over 4 years is -$3.2 million, with a median of -$2.5 million recorded in 2023.
• Year-over-year, Net Income towards Common Stockholders tumbled 245.02% in 2025 and surged 71.86% in 2026.
• Over 4 years, Net Income towards Common Stockholders stood at -$2.6 million in 2023, then rose by 24.13% to -$1.9 million in 2024, then plunged by 57.24% to -$3.1 million in 2025, then soared by 47.56% to -$1.6 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$1.6 million in Q2 2026, -$3.7 million in Q1 2026, and -$3.1 million in Q4 2025.